Anavex Life Sciences News

Earnings Preview: AVXL to Report Financial Results Pre-market on December 23

Moomoo NewsDec 17 20:00 ET

Anavex Life Sciences Corp. to Announce Fiscal Year 2024 Financial Results on December 23, 2024

Quiver QuantitativeDec 16 07:41 ET

Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer's Disease Data at J.P. Morgan 2025 Healthcare Conference

GlobeNewswireDec 9 07:30 ET

Earnings Week Ahead: ORCL, GME, ADBE, COST, AVGO, M and More

Seeking AlphaDec 8 08:01 ET

Anavex Life Sciences Down Over 13%, On Track for Largest Percent Decrease Since January -- Data Talk

Dow JonesDec 5 15:12 ET

Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024

GlobeNewswireDec 2 07:30 ET

Buy Recommendation for Anavex Life Sciences: Promising Alzheimer's Treatment and Expanding Clinical Pipeline

TipRanksNov 27 06:25 ET

Anavex Submits Marketing Authorization Application to EU Regulator for Blarcamesine to Treat Alzheimer's; Shares Jump Pre-Bell

MT NewswiresNov 26 09:29 ET

Express News | Anavex Life Sciences Announces Submission of Blarcamesine Maa for Treatment of Alzheimer’s Disease to EMA

ReutersNov 26 07:30 ET

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow JonesNov 25 09:15 ET · Ratings

Anavex Life Sciences Price Target Maintained With a $46.00/Share by D. Boral Capital

Dow JonesNov 25 09:15 ET · Ratings

Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal

GlobeNewswireNov 25 07:30 ET

Express News | Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase Iib/III Data in a Reference Alzheimer’s Disease Journal

ReutersNov 25 07:30 ET

Calendar of U.S. Earnings Expected in the Week Ahead

Dow JonesNov 22 06:00 ET

Earnings Week Ahead: NVDA, WMT, SNOW, TGT, BIDU, NIO, ZIM, and More

Seeking AlphaNov 18 00:09 ET

Anavex Life Sciences Corp. (NASDAQ:AVXL): Is Breakeven Near?

Simply Wall StNov 6 08:08 ET

Express News | HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $40 Price Target

BenzingaNov 4 06:29 ET

Anavex Life Sciences: Buy Rating Driven by Promising Blarcamesine Developments and Market Expansion

TipRanksNov 4 06:15 ET · Ratings

Anavex Life Sciences Shares Are Trading Higher After the Company Announced New Data From the Phase IIb/III Study Showing That Blarcamesine, Once Daily Orally, Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation.

BenzingaOct 31 14:58 ET

12 Health Care Stocks Moving In Thursday's Intraday Session

BenzingaOct 31 12:34 ET